Washington, 03 April (H.S.):

US President Donald Trump has intensified his economic nationalism by signing executive orders that impose steep tariffs on foreign-made patented pharmaceuticals and restructure duties on key metals, compelling global manufacturers to relocate production stateside.

These measures, unveiled on the anniversary of last year's sweeping Liberation Day tariff announcements—which were later invalidated by the Supreme Court—signal Trump's determination to revive American industry through aggressive trade policy, even as critics question their impact on jobs and consumer costs.

The pharmaceutical directive levies a 100 percent tariff on imported patented drugs unless companies submit reshoring plans to build US facilities by the end of his second term; larger firms get 120 days to comply, smaller ones 180, with compliant operations facing a reduced 20 percent duty.

Exemptions apply to generics for now and to nations like the European Union, Japan, South Korea, and Switzerland via prior trade pacts, while Britain gains three years of tariff-free access under a fresh agreement; drugmakers securing Most Favored Nation pricing alongside US plants could dodge penalties altogether.

A parallel order overhauls 50 percent tariffs on steel, aluminum, and copper, basing them on US buyer prices to counter alleged foreign price manipulation, while finished goods exceeding 15 percent metal content now incur a flat 25 percent levy on full value for administrative simplicity.

Set to activate Monday at 12:01 a.m. Eastern Time, officials insist these changes shield households from price hikes amid midterm election pressures, framing them as fairness reforms rather than cost drivers.

Trump's actions dovetail with his broader Middle East brinkmanship, where recent rhetoric on Iran—warning of further strikes and rejecting concessions on the Strait of Hormuz,underscores a pattern of high-stakes pressure tactics across fronts.

Yet administration spokespeople emphasize that pharmaceutical reshoring will dominate global patented drug production without inflating shelf prices, betting on long-term industrial gains over short-term disruptions.

---------------

Hindusthan Samachar / Jun Sarkar